Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study
Neurological conditions represent an important driver of paediatric disability burden worldwide. Measurement of serum neurofilament light chain (sNfL) concentrations, a specific marker of neuroaxonal injury, has the potential to contribute to the management of children with such conditions. In this...
Gespeichert in:
| Veröffentlicht in: | Lancet neurology 2023-09, Vol.22 (9), p.826-833 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 833 |
|---|---|
| container_issue | 9 |
| container_start_page | 826 |
| container_title | Lancet neurology |
| container_volume | 22 |
| creator | Abdelhak, Ahmed Petermeier, Franziska Benkert, Pascal Schädelin, Sabine Oechtering, Johanna Maleska Maceski, Aleksandra Kabesch, Michael Geis, Tobias Laub, Otto Leipold, Georg Gobbi, Claudio Zecca, Chiara Green, Ari Tumani, Hayrettin Willemse, Eline Wiendl, Heinz Granziera, Cristina Kappos, Ludwig Leppert, David Waubant, Emmanuelle Wellmann, Sven Kuhle, Jens |
| description | Neurological conditions represent an important driver of paediatric disability burden worldwide. Measurement of serum neurofilament light chain (sNfL) concentrations, a specific marker of neuroaxonal injury, has the potential to contribute to the management of children with such conditions. In this context, the European Medicines Agency recently declared age-adjusted reference values for sNfL a top research priority. We aimed to establish an age-adjusted sNfL reference range database in a population of healthy children and adolescents, and to validate this database in paediatric patients with neurological conditions to affirm its clinical applicability.
To generate a paediatric sNfL reference dataset, sNfL values were measured in a population of healthy children and adolescents (aged 0–22 years) from two large cohorts in Europe (the Coronavirus Antibodies in Kids from Bavaria study, Germany) and North America (a US Network of Paediatric Multiple Sclerosis Centers paediatric case-control cohort). Children with active or previous COVID-19 infection or SARS-CoV-2 antibody positivity at the time of sampling, or a history of primary systemic or neurological conditions were excluded. Linear models were used to restrospectively study the effect of age and weight on sNfL concentrations. We modelled the distribution of sNfL concentrations as a function of age-related physiological changes to derive reference percentile and Z score values via a generalised additive model for location, scale, and shape. The clinical utility of the new reference dataset was assessed in children and adolescents (aged 1–19 years) with neurological diseases (epilepsy, traumatic brain injury, bacterial CNS infections, paediatric-onset multiple sclerosis, and myelin oligodendrocyte glycoprotein antibody-associated disease) from the paediatric neuroimmunology clinic at the University of California San Francisco (San Francisco, CA, USA) and the Children's Hospital of the University of Regensburg (Regensburg, Germany).
Samples from 2667 healthy children and adolescents (1336 [50·1%] girls and 1331 [49·9%] boys; median age 8·0 years [IQR 4·0–12·0]) were used to generate the reference database covering neonatal age to adolescence (target age range 0–20 years). In the healthy population, sNfL concentrations decreased with age by an estimated 6·8% per year until age 10·3 years (estimated multiplicative effect per 1 year increase 0·93 [95% CI 0·93–0·94], p |
| doi_str_mv | 10.1016/S1474-4422(23)00210-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2844680408</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1474442223002107</els_id><sourcerecordid>2851844714</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-fe257fe87e95eb9130e6fa784f4b40ee9701521130dbcfed5fb782c05a5b01c3</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhSMEoqXwCCBLbMoiYDv2OMMGoYo_qRKLdm_d2NftrRIn2M5IfQseGU9n6IINK1tX3zm-PqdpXgv-XnCx-XAllFGtUlKey-4d51Lw1jxpTo_jjX76eJfypHmR890eUr143px0RkslOD9tfl9hWicWcU1zoBEmjIWNdHNbmLsFiixhwITRIfNQYICMLMyJUfS0I7_CyGBZRnJQaI51zBZAT1ASOeYg4UcG1aOkOS_oCu2QTbPHcaR4wyB6toOR_EGcy-rvXzbPAowZXx3Ps-b665fri-_t5c9vPy4-X7ZOKV7agFKbgL3BrcZhKzqOmwCmV0ENiiNuDRdaijr3gwvodRhMLx3XoAcuXHfWnB9slzT_WjEXO1F2dS-IOK_Zyr5m2HPF-4q-_Qe9m9cU63KV0qKCRqhK6QPl6ldzTc0uiSZI91Zwu2_MPjRm93VY2dmHxqypujdH93WY0D-q_lZUgU8HAGsaO8Jks6N9IZ5STdT6mf7zxB9cOKhP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2851844714</pqid></control><display><type>article</type><title>Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study</title><source>Elsevier ScienceDirect Journals</source><creator>Abdelhak, Ahmed ; Petermeier, Franziska ; Benkert, Pascal ; Schädelin, Sabine ; Oechtering, Johanna ; Maleska Maceski, Aleksandra ; Kabesch, Michael ; Geis, Tobias ; Laub, Otto ; Leipold, Georg ; Gobbi, Claudio ; Zecca, Chiara ; Green, Ari ; Tumani, Hayrettin ; Willemse, Eline ; Wiendl, Heinz ; Granziera, Cristina ; Kappos, Ludwig ; Leppert, David ; Waubant, Emmanuelle ; Wellmann, Sven ; Kuhle, Jens</creator><creatorcontrib>Abdelhak, Ahmed ; Petermeier, Franziska ; Benkert, Pascal ; Schädelin, Sabine ; Oechtering, Johanna ; Maleska Maceski, Aleksandra ; Kabesch, Michael ; Geis, Tobias ; Laub, Otto ; Leipold, Georg ; Gobbi, Claudio ; Zecca, Chiara ; Green, Ari ; Tumani, Hayrettin ; Willemse, Eline ; Wiendl, Heinz ; Granziera, Cristina ; Kappos, Ludwig ; Leppert, David ; Waubant, Emmanuelle ; Wellmann, Sven ; Kuhle, Jens</creatorcontrib><description>Neurological conditions represent an important driver of paediatric disability burden worldwide. Measurement of serum neurofilament light chain (sNfL) concentrations, a specific marker of neuroaxonal injury, has the potential to contribute to the management of children with such conditions. In this context, the European Medicines Agency recently declared age-adjusted reference values for sNfL a top research priority. We aimed to establish an age-adjusted sNfL reference range database in a population of healthy children and adolescents, and to validate this database in paediatric patients with neurological conditions to affirm its clinical applicability.
To generate a paediatric sNfL reference dataset, sNfL values were measured in a population of healthy children and adolescents (aged 0–22 years) from two large cohorts in Europe (the Coronavirus Antibodies in Kids from Bavaria study, Germany) and North America (a US Network of Paediatric Multiple Sclerosis Centers paediatric case-control cohort). Children with active or previous COVID-19 infection or SARS-CoV-2 antibody positivity at the time of sampling, or a history of primary systemic or neurological conditions were excluded. Linear models were used to restrospectively study the effect of age and weight on sNfL concentrations. We modelled the distribution of sNfL concentrations as a function of age-related physiological changes to derive reference percentile and Z score values via a generalised additive model for location, scale, and shape. The clinical utility of the new reference dataset was assessed in children and adolescents (aged 1–19 years) with neurological diseases (epilepsy, traumatic brain injury, bacterial CNS infections, paediatric-onset multiple sclerosis, and myelin oligodendrocyte glycoprotein antibody-associated disease) from the paediatric neuroimmunology clinic at the University of California San Francisco (San Francisco, CA, USA) and the Children's Hospital of the University of Regensburg (Regensburg, Germany).
Samples from 2667 healthy children and adolescents (1336 [50·1%] girls and 1331 [49·9%] boys; median age 8·0 years [IQR 4·0–12·0]) were used to generate the reference database covering neonatal age to adolescence (target age range 0–20 years). In the healthy population, sNfL concentrations decreased with age by an estimated 6·8% per year until age 10·3 years (estimated multiplicative effect per 1 year increase 0·93 [95% CI 0·93–0·94], p<0·0001) and was mostly stable thereafter up to age 22 years (1·00 [0·52–1·94], p>0·99). Independent of age, the magnitude of the effect of weight on sNfL concentrations was marginal. Samples from 220 children with neurological conditions (134 [60·9%] girls and 86 [39·1%] boys; median age 14·7 years [IQR 10·8–16·5]) were used to validate the clinical utility of the reference Z scores. In this population, age-adjusted sNfL Z scores were higher than in the reference population of healthy children and adolescents (p<0·0001) with higher effect size metrics (Cohen's d=1·56) compared with the application of raw sNfL concentrations (d=1·28).
The established normative sNfL values in children and adolescents provide a foundation for the clinical application of sNfL in the paediatric population. Compared with absolute sNfL values, the use of sNfL Z score was associated with higher effect size metrics and allowed for more accurate estimation of the extent of ongoing neuroaxonal damage in individual patients.
Swiss National Science Foundation, US National Institutes of Health, and the National Multiple Sclerosis Society.</description><identifier>ISSN: 1474-4422</identifier><identifier>EISSN: 1474-4465</identifier><identifier>DOI: 10.1016/S1474-4422(23)00210-7</identifier><identifier>PMID: 37524100</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adolescence ; Adolescents ; Age ; Antibodies ; Biomarkers ; Children ; Coronaviruses ; COVID-19 ; Datasets ; Dependent variables ; Disease ; Epilepsy ; Glycoproteins ; Health care ; Multiple sclerosis ; Myelin ; Neonates ; Neuroimmunology ; Neurological diseases ; Oligodendrocyte-myelin glycoprotein ; Patients ; Pediatrics ; Population ; Severe acute respiratory syndrome coronavirus 2 ; Teenagers ; Traumatic brain injury</subject><ispartof>Lancet neurology, 2023-09, Vol.22 (9), p.826-833</ispartof><rights>2023 Elsevier Ltd</rights><rights>Copyright © 2023 Elsevier Ltd. All rights reserved.</rights><rights>2023. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-fe257fe87e95eb9130e6fa784f4b40ee9701521130dbcfed5fb782c05a5b01c3</citedby><cites>FETCH-LOGICAL-c440t-fe257fe87e95eb9130e6fa784f4b40ee9701521130dbcfed5fb782c05a5b01c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1474442223002107$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37524100$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdelhak, Ahmed</creatorcontrib><creatorcontrib>Petermeier, Franziska</creatorcontrib><creatorcontrib>Benkert, Pascal</creatorcontrib><creatorcontrib>Schädelin, Sabine</creatorcontrib><creatorcontrib>Oechtering, Johanna</creatorcontrib><creatorcontrib>Maleska Maceski, Aleksandra</creatorcontrib><creatorcontrib>Kabesch, Michael</creatorcontrib><creatorcontrib>Geis, Tobias</creatorcontrib><creatorcontrib>Laub, Otto</creatorcontrib><creatorcontrib>Leipold, Georg</creatorcontrib><creatorcontrib>Gobbi, Claudio</creatorcontrib><creatorcontrib>Zecca, Chiara</creatorcontrib><creatorcontrib>Green, Ari</creatorcontrib><creatorcontrib>Tumani, Hayrettin</creatorcontrib><creatorcontrib>Willemse, Eline</creatorcontrib><creatorcontrib>Wiendl, Heinz</creatorcontrib><creatorcontrib>Granziera, Cristina</creatorcontrib><creatorcontrib>Kappos, Ludwig</creatorcontrib><creatorcontrib>Leppert, David</creatorcontrib><creatorcontrib>Waubant, Emmanuelle</creatorcontrib><creatorcontrib>Wellmann, Sven</creatorcontrib><creatorcontrib>Kuhle, Jens</creatorcontrib><title>Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study</title><title>Lancet neurology</title><addtitle>Lancet Neurol</addtitle><description>Neurological conditions represent an important driver of paediatric disability burden worldwide. Measurement of serum neurofilament light chain (sNfL) concentrations, a specific marker of neuroaxonal injury, has the potential to contribute to the management of children with such conditions. In this context, the European Medicines Agency recently declared age-adjusted reference values for sNfL a top research priority. We aimed to establish an age-adjusted sNfL reference range database in a population of healthy children and adolescents, and to validate this database in paediatric patients with neurological conditions to affirm its clinical applicability.
To generate a paediatric sNfL reference dataset, sNfL values were measured in a population of healthy children and adolescents (aged 0–22 years) from two large cohorts in Europe (the Coronavirus Antibodies in Kids from Bavaria study, Germany) and North America (a US Network of Paediatric Multiple Sclerosis Centers paediatric case-control cohort). Children with active or previous COVID-19 infection or SARS-CoV-2 antibody positivity at the time of sampling, or a history of primary systemic or neurological conditions were excluded. Linear models were used to restrospectively study the effect of age and weight on sNfL concentrations. We modelled the distribution of sNfL concentrations as a function of age-related physiological changes to derive reference percentile and Z score values via a generalised additive model for location, scale, and shape. The clinical utility of the new reference dataset was assessed in children and adolescents (aged 1–19 years) with neurological diseases (epilepsy, traumatic brain injury, bacterial CNS infections, paediatric-onset multiple sclerosis, and myelin oligodendrocyte glycoprotein antibody-associated disease) from the paediatric neuroimmunology clinic at the University of California San Francisco (San Francisco, CA, USA) and the Children's Hospital of the University of Regensburg (Regensburg, Germany).
Samples from 2667 healthy children and adolescents (1336 [50·1%] girls and 1331 [49·9%] boys; median age 8·0 years [IQR 4·0–12·0]) were used to generate the reference database covering neonatal age to adolescence (target age range 0–20 years). In the healthy population, sNfL concentrations decreased with age by an estimated 6·8% per year until age 10·3 years (estimated multiplicative effect per 1 year increase 0·93 [95% CI 0·93–0·94], p<0·0001) and was mostly stable thereafter up to age 22 years (1·00 [0·52–1·94], p>0·99). Independent of age, the magnitude of the effect of weight on sNfL concentrations was marginal. Samples from 220 children with neurological conditions (134 [60·9%] girls and 86 [39·1%] boys; median age 14·7 years [IQR 10·8–16·5]) were used to validate the clinical utility of the reference Z scores. In this population, age-adjusted sNfL Z scores were higher than in the reference population of healthy children and adolescents (p<0·0001) with higher effect size metrics (Cohen's d=1·56) compared with the application of raw sNfL concentrations (d=1·28).
The established normative sNfL values in children and adolescents provide a foundation for the clinical application of sNfL in the paediatric population. Compared with absolute sNfL values, the use of sNfL Z score was associated with higher effect size metrics and allowed for more accurate estimation of the extent of ongoing neuroaxonal damage in individual patients.
Swiss National Science Foundation, US National Institutes of Health, and the National Multiple Sclerosis Society.</description><subject>Adolescence</subject><subject>Adolescents</subject><subject>Age</subject><subject>Antibodies</subject><subject>Biomarkers</subject><subject>Children</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Datasets</subject><subject>Dependent variables</subject><subject>Disease</subject><subject>Epilepsy</subject><subject>Glycoproteins</subject><subject>Health care</subject><subject>Multiple sclerosis</subject><subject>Myelin</subject><subject>Neonates</subject><subject>Neuroimmunology</subject><subject>Neurological diseases</subject><subject>Oligodendrocyte-myelin glycoprotein</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Population</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Teenagers</subject><subject>Traumatic brain injury</subject><issn>1474-4422</issn><issn>1474-4465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqFkc1u1DAUhSMEoqXwCCBLbMoiYDv2OMMGoYo_qRKLdm_d2NftrRIn2M5IfQseGU9n6IINK1tX3zm-PqdpXgv-XnCx-XAllFGtUlKey-4d51Lw1jxpTo_jjX76eJfypHmR890eUr143px0RkslOD9tfl9hWicWcU1zoBEmjIWNdHNbmLsFiixhwITRIfNQYICMLMyJUfS0I7_CyGBZRnJQaI51zBZAT1ASOeYg4UcG1aOkOS_oCu2QTbPHcaR4wyB6toOR_EGcy-rvXzbPAowZXx3Ps-b665fri-_t5c9vPy4-X7ZOKV7agFKbgL3BrcZhKzqOmwCmV0ENiiNuDRdaijr3gwvodRhMLx3XoAcuXHfWnB9slzT_WjEXO1F2dS-IOK_Zyr5m2HPF-4q-_Qe9m9cU63KV0qKCRqhK6QPl6ldzTc0uiSZI91Zwu2_MPjRm93VY2dmHxqypujdH93WY0D-q_lZUgU8HAGsaO8Jks6N9IZ5STdT6mf7zxB9cOKhP</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Abdelhak, Ahmed</creator><creator>Petermeier, Franziska</creator><creator>Benkert, Pascal</creator><creator>Schädelin, Sabine</creator><creator>Oechtering, Johanna</creator><creator>Maleska Maceski, Aleksandra</creator><creator>Kabesch, Michael</creator><creator>Geis, Tobias</creator><creator>Laub, Otto</creator><creator>Leipold, Georg</creator><creator>Gobbi, Claudio</creator><creator>Zecca, Chiara</creator><creator>Green, Ari</creator><creator>Tumani, Hayrettin</creator><creator>Willemse, Eline</creator><creator>Wiendl, Heinz</creator><creator>Granziera, Cristina</creator><creator>Kappos, Ludwig</creator><creator>Leppert, David</creator><creator>Waubant, Emmanuelle</creator><creator>Wellmann, Sven</creator><creator>Kuhle, Jens</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20230901</creationdate><title>Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study</title><author>Abdelhak, Ahmed ; Petermeier, Franziska ; Benkert, Pascal ; Schädelin, Sabine ; Oechtering, Johanna ; Maleska Maceski, Aleksandra ; Kabesch, Michael ; Geis, Tobias ; Laub, Otto ; Leipold, Georg ; Gobbi, Claudio ; Zecca, Chiara ; Green, Ari ; Tumani, Hayrettin ; Willemse, Eline ; Wiendl, Heinz ; Granziera, Cristina ; Kappos, Ludwig ; Leppert, David ; Waubant, Emmanuelle ; Wellmann, Sven ; Kuhle, Jens</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-fe257fe87e95eb9130e6fa784f4b40ee9701521130dbcfed5fb782c05a5b01c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adolescence</topic><topic>Adolescents</topic><topic>Age</topic><topic>Antibodies</topic><topic>Biomarkers</topic><topic>Children</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Datasets</topic><topic>Dependent variables</topic><topic>Disease</topic><topic>Epilepsy</topic><topic>Glycoproteins</topic><topic>Health care</topic><topic>Multiple sclerosis</topic><topic>Myelin</topic><topic>Neonates</topic><topic>Neuroimmunology</topic><topic>Neurological diseases</topic><topic>Oligodendrocyte-myelin glycoprotein</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Population</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Teenagers</topic><topic>Traumatic brain injury</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdelhak, Ahmed</creatorcontrib><creatorcontrib>Petermeier, Franziska</creatorcontrib><creatorcontrib>Benkert, Pascal</creatorcontrib><creatorcontrib>Schädelin, Sabine</creatorcontrib><creatorcontrib>Oechtering, Johanna</creatorcontrib><creatorcontrib>Maleska Maceski, Aleksandra</creatorcontrib><creatorcontrib>Kabesch, Michael</creatorcontrib><creatorcontrib>Geis, Tobias</creatorcontrib><creatorcontrib>Laub, Otto</creatorcontrib><creatorcontrib>Leipold, Georg</creatorcontrib><creatorcontrib>Gobbi, Claudio</creatorcontrib><creatorcontrib>Zecca, Chiara</creatorcontrib><creatorcontrib>Green, Ari</creatorcontrib><creatorcontrib>Tumani, Hayrettin</creatorcontrib><creatorcontrib>Willemse, Eline</creatorcontrib><creatorcontrib>Wiendl, Heinz</creatorcontrib><creatorcontrib>Granziera, Cristina</creatorcontrib><creatorcontrib>Kappos, Ludwig</creatorcontrib><creatorcontrib>Leppert, David</creatorcontrib><creatorcontrib>Waubant, Emmanuelle</creatorcontrib><creatorcontrib>Wellmann, Sven</creatorcontrib><creatorcontrib>Kuhle, Jens</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Lancet neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdelhak, Ahmed</au><au>Petermeier, Franziska</au><au>Benkert, Pascal</au><au>Schädelin, Sabine</au><au>Oechtering, Johanna</au><au>Maleska Maceski, Aleksandra</au><au>Kabesch, Michael</au><au>Geis, Tobias</au><au>Laub, Otto</au><au>Leipold, Georg</au><au>Gobbi, Claudio</au><au>Zecca, Chiara</au><au>Green, Ari</au><au>Tumani, Hayrettin</au><au>Willemse, Eline</au><au>Wiendl, Heinz</au><au>Granziera, Cristina</au><au>Kappos, Ludwig</au><au>Leppert, David</au><au>Waubant, Emmanuelle</au><au>Wellmann, Sven</au><au>Kuhle, Jens</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study</atitle><jtitle>Lancet neurology</jtitle><addtitle>Lancet Neurol</addtitle><date>2023-09-01</date><risdate>2023</risdate><volume>22</volume><issue>9</issue><spage>826</spage><epage>833</epage><pages>826-833</pages><issn>1474-4422</issn><eissn>1474-4465</eissn><abstract>Neurological conditions represent an important driver of paediatric disability burden worldwide. Measurement of serum neurofilament light chain (sNfL) concentrations, a specific marker of neuroaxonal injury, has the potential to contribute to the management of children with such conditions. In this context, the European Medicines Agency recently declared age-adjusted reference values for sNfL a top research priority. We aimed to establish an age-adjusted sNfL reference range database in a population of healthy children and adolescents, and to validate this database in paediatric patients with neurological conditions to affirm its clinical applicability.
To generate a paediatric sNfL reference dataset, sNfL values were measured in a population of healthy children and adolescents (aged 0–22 years) from two large cohorts in Europe (the Coronavirus Antibodies in Kids from Bavaria study, Germany) and North America (a US Network of Paediatric Multiple Sclerosis Centers paediatric case-control cohort). Children with active or previous COVID-19 infection or SARS-CoV-2 antibody positivity at the time of sampling, or a history of primary systemic or neurological conditions were excluded. Linear models were used to restrospectively study the effect of age and weight on sNfL concentrations. We modelled the distribution of sNfL concentrations as a function of age-related physiological changes to derive reference percentile and Z score values via a generalised additive model for location, scale, and shape. The clinical utility of the new reference dataset was assessed in children and adolescents (aged 1–19 years) with neurological diseases (epilepsy, traumatic brain injury, bacterial CNS infections, paediatric-onset multiple sclerosis, and myelin oligodendrocyte glycoprotein antibody-associated disease) from the paediatric neuroimmunology clinic at the University of California San Francisco (San Francisco, CA, USA) and the Children's Hospital of the University of Regensburg (Regensburg, Germany).
Samples from 2667 healthy children and adolescents (1336 [50·1%] girls and 1331 [49·9%] boys; median age 8·0 years [IQR 4·0–12·0]) were used to generate the reference database covering neonatal age to adolescence (target age range 0–20 years). In the healthy population, sNfL concentrations decreased with age by an estimated 6·8% per year until age 10·3 years (estimated multiplicative effect per 1 year increase 0·93 [95% CI 0·93–0·94], p<0·0001) and was mostly stable thereafter up to age 22 years (1·00 [0·52–1·94], p>0·99). Independent of age, the magnitude of the effect of weight on sNfL concentrations was marginal. Samples from 220 children with neurological conditions (134 [60·9%] girls and 86 [39·1%] boys; median age 14·7 years [IQR 10·8–16·5]) were used to validate the clinical utility of the reference Z scores. In this population, age-adjusted sNfL Z scores were higher than in the reference population of healthy children and adolescents (p<0·0001) with higher effect size metrics (Cohen's d=1·56) compared with the application of raw sNfL concentrations (d=1·28).
The established normative sNfL values in children and adolescents provide a foundation for the clinical application of sNfL in the paediatric population. Compared with absolute sNfL values, the use of sNfL Z score was associated with higher effect size metrics and allowed for more accurate estimation of the extent of ongoing neuroaxonal damage in individual patients.
Swiss National Science Foundation, US National Institutes of Health, and the National Multiple Sclerosis Society.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>37524100</pmid><doi>10.1016/S1474-4422(23)00210-7</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1474-4422 |
| ispartof | Lancet neurology, 2023-09, Vol.22 (9), p.826-833 |
| issn | 1474-4422 1474-4465 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2844680408 |
| source | Elsevier ScienceDirect Journals |
| subjects | Adolescence Adolescents Age Antibodies Biomarkers Children Coronaviruses COVID-19 Datasets Dependent variables Disease Epilepsy Glycoproteins Health care Multiple sclerosis Myelin Neonates Neuroimmunology Neurological diseases Oligodendrocyte-myelin glycoprotein Patients Pediatrics Population Severe acute respiratory syndrome coronavirus 2 Teenagers Traumatic brain injury |
| title | Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T03%3A53%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20neurofilament%20light%20chain%20reference%20database%20for%20individual%20application%20in%20paediatric%20care:%20a%20retrospective%20modelling%20and%20validation%20study&rft.jtitle=Lancet%20neurology&rft.au=Abdelhak,%20Ahmed&rft.date=2023-09-01&rft.volume=22&rft.issue=9&rft.spage=826&rft.epage=833&rft.pages=826-833&rft.issn=1474-4422&rft.eissn=1474-4465&rft_id=info:doi/10.1016/S1474-4422(23)00210-7&rft_dat=%3Cproquest_cross%3E2851844714%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2851844714&rft_id=info:pmid/37524100&rft_els_id=S1474442223002107&rfr_iscdi=true |